We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





DRG Unveils Innovative Traumatic Brain Injury (TBI) Test Panel

By LabMedica International staff writers
Posted on 04 Feb 2025
Print article
Image: DRG is introducing the 30-minute time to result CE-marked tests for suspected mTBI patients (Photo courtesy of DRG)
Image: DRG is introducing the 30-minute time to result CE-marked tests for suspected mTBI patients (Photo courtesy of DRG)

DRG Instruments (Marburg, Germany is unveiling its fully automated CLIA tests for evaluating suspected Traumatic Brain Injury (TBI) - the GFAP and UCH-L1 combo Tests – at Medlab Middle East 2025.

TBI can be mild or severe and is defined as damage to the brain resulting from an external mechanical force, such as rapid acceleration or deceleration, impact, blast waves, or penetration by a projectile. Imaging tests such as an MRI or CT scan can be performed, but these cannot detect all TBIs. This is of particular concern for those TBIs categorized as mild. Patients with mild TBI may suffer acute brain injury termed diffuse axonal injury (DAI), also known as “shearing injury,” which is not visible on standard CT and MRI scans. DAI is defined as “diffuse damage to axons in the cerebral hemispheres, in the corpus callosum, in the brainstem, and sometimes also in the cerebellum resulting from a head injury.” Brain injury biomarkers such as GFAP and UCH-L1 have effectively shown to help health care providers in providing immediate standard of care to evaluate and treat patients.

GFAP is released when astrocytes are damaged, making it a specific marker for astroglial injury, which occurs in moderate to severe TBI. Blood levels of GFAP increase soon after injury and remain elevated longer than UCH-L1, providing a longer window for detection. UCH-L1 is released into the bloodstream following neuronal injury, making it a reliable marker for neuronal damage in TBI. Elevated levels of UCH-L1 in the blood can be detected within hours after an injury, helping doctors diagnose mild to moderate TBI and differentiate it from non-brain injuries. The GFAP and UCH-L1 combo tests are designed for use on DRG's automated CLIA platform, DxDATA, enabling the measurement of GFAP and UCH-L1 blood levels within 30 minutes when patients' serum samples are collected within 12 hours of suspected traumatic brain injury. By providing fast and accurate TBI assessments, these tests increase the likelihood of immediate and effective treatment while reducing the need for radiation-based diagnostic imaging for suspected TBI.

"We are excited to bring these innovative TBI solutions to the global market," said Joerg Schloesser, Managing Director and VP of Commercial. "By leveraging automated testing and rapid turnaround times, we can help healthcare professionals make quicker, more informed decisions. Our mission is to advance patient care for those affected by traumatic brain injuries worldwide."

Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Epstein-Barr Virus Assay
Panther Fusion EBV Quant Assay
New
Gastrointestinal Infection Test
RIDA QUICK Cryptosporidium/Giardia/Entamoeba Combi Test

Print article

Channels

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Pathology

view channel
Image: The OmicsFootPrint AI tool could open doors to new discoveries (Photo courtesy of Mayo Clinic)

Revolutionary AI Tool Transforms Disease Visualization

Genes serve as the body's blueprint, while proteins execute the instructions within those blueprints to maintain cell function. Occasionally, alterations in these instructions—known as mutations—can interfere... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.